. Earth Science News .
EPIDEMICS
Scientists report big improvements in HIV vaccine production
by Staff Writers
Santa Cruz CA (SPX) Feb 06, 2018

Fluorescent antibodies were used to label the HIV gp120 protein and identify high-producing cell lines.

Research on HIV over the past decade has led to many promising ideas for vaccines to prevent infection by the AIDS virus, but very few candidate vaccines have been tested in clinical trials.

One reason for this is the technical difficulty of manufacturing vaccines based on the envelope proteins of the virus, according to Phil Berman, who led development of a major component of the only vaccine to have shown any efficacy against HIV in a clinical trial.

Berman, the Baskin Professor of Biomolecular Engineering at UC Santa Cruz, has now developed new methods for the production of HIV vaccines. His approach solves major technical problems which have bedeviled the field.

Berman described the new methods, and the candidate vaccines his lab has produced, in a talk at a conference on HIV vaccines held last week in Canada ("Emerging Technologies in Vaccine Discovery and Development," a joint meeting with "Progress and Pathways Toward an Effective HIV Vaccine," January 28 to February 1 in Banff, Alberta, part of the Keystone Symposia Global Health Series).

"Dozens of interesting vaccine candidates have been described, but most have not been tested in humans because it has not previously been possible to manufacture them affordably and in a timely fashion," Berman said.

"The technology we developed should break the logjam in HIV vaccine development, because it tremendously shortens the time, improves the yield, and lowers the cost."

Berman's lab was able to use robotics to shorten the time required to produce stable cell lines, needed to make the proteins for a vaccine, while at the same time greatly increasing how much of the protein the cell lines can produce.

The improved yield makes it possible to reduce the size of the bioreactor needed to make vaccine for large clinical trials - from 200- to 10,000-liter vessels to 50- or 100-liter vessels - resulting in tremendous savings in the equipment required and cost of materials.

In addition, Berman's lab was able to create cell lines that make HIV envelope proteins with the right kind of carbohydrate components (called glycans) needed for an effective immune response.

"The carbohydrates attached to the protein are really important, something no one realized until recently," Berman said.

"The conventional way of making these envelope protein vaccines incorporated the wrong kind of carbohydrates. We now know that destroyed many of the important antigenic sites recognized by protective antibodies."

Cell lines derived from Chinese hamster ovary (CHO) cells are the industry standard used to produce complex recombinant proteins for therapeutic use. These cells are also useful for the production of HIV vaccines.

The gene for the desired protein is transferred into CHO cells in a process called transfection, and tens of thousands of transfected cells are screened to find the few rare cells that produce large amounts of the protein. The best cell lines are grown in large batches, in a process similar to yeast fermentation for making beer, and the proteins are then isolated and purified.

Berman's lab developed a new robotic method to isolate high-producing cell lines making HIV envelope proteins. This shortened the time required to produce stable cell lines from 18 to 24 months to just 2 or 3 months, while increasing yields by a factor of 100 to 200. Those improvements are in comparison with Berman's previous experience creating the AIDSVAX vaccine, first at Genentech and then at VaxGen.

AIDSVAX was one component of an experimental vaccine regimen used in a large-scale clinical trial known as RV144, which showed 31 percent efficacy in preventing new HIV infections. The RV144 results showed that protection was correlated with antibodies to a certain segment of an HIV envelope protein called gp120.

Other research, however, revealed that many of the most potent antibodies (broadly neutralizing antibodies capable of neutralizing many different strains of HIV) actually recognize the carbohydrate components (glycans) attached to gp120.

"We realized that the original AIDSVAX vaccine had the completely wrong type of carbohydrate, and that we might improve the level of protection if we could find a way to make it with the proper type of carbohydrate," Berman said.

So he and graduate student Gabriel Byrne set out to create a cell line that can produce the unusual glycans found on HIV envelope proteins rather than the complex glycans CHO cells normally produce.

This was made possible by the powerful new gene editing technology known as CRISPR/Cas9. Berman's lab used CRISPR to create a new cell line they called MGAT CHO, which produces proteins lacking complex glycans containing sialic acid and enriched for the simple "high mannose" type found on HIV envelope proteins. An unexpected benefit of this new cell line was that it enabled a simpler, less expensive process for recovering and purifying the proteins.

"People used to think carbohydrates are not immunogenic, but HIV turns everything on its head, and it turns out that the most important antibodies are directed to this unusual carbohydrate," Berman said.

"We can now make vaccines with it for the first time, and we've created an improved version of the vaccine used in the RV144 trial. Our hope is that it will bring the efficacy up from 31 percent to greater than 50 percent, the level likely required for product registration."

Berman's lab currently has two cell lines he said are ready to start producing vaccines on a large scale. He is now looking for partners and funding to bring them into clinical trials.

One vaccine is an improved version of AIDSVAX that incorporates the right kind of glycans. The other is made from a strain of the virus called Clade C that is widespread in Southern Africa and India and accounts for the majority of new HIV infections worldwide.

Researchers have continued to use the AIDSVAX vaccine in clinical studies because it has been so hard to make new HIV vaccines, Berman said, noting that there have been 14 such studies since the RV144 results were released in 2009.

"They're still using that same old vaccine we made in the early 1990s. Although the stability and safety of the product is testament to the quality of the vaccine we made, new vaccines are required that take advantage of all that we have learned since that time," he said.

"It just emphasizes the need to find a more efficient way to make an HIV vaccine."

In addition to Berman's talk, several other members of his lab presented details of their methods and findings at the conference. Berman said they expect to publish their findings in several papers later this year. This research was funded by major grants from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.


Related Links
University of California - Santa Cruz
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola


Thanks for being here;
We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor
$5 Billed Once


credit card or paypal
SpaceDaily Monthly Supporter
$5 Billed Monthly


paypal only


EPIDEMICS
Plague outbreak in Madagascar revived dread of a killer
Antananarivo (AFP) Jan 26, 2018
Most inhabitants of Madagascar thought the plague was a footnote of medical history until the disease dramatically returned last year, slaying more than 200 people. Fear and anxiety rippled across the Indian Ocean island nation. "People were afraid to come to hospital - they were afraid of catching the plague," recalled Professor Mamy Randria, head of the infectious diseases service at a hospital in the capital Antananarivo. Randria found himself on the front line of an urban war against t ... read more

Comment using your Disqus, Facebook, Google or Twitter login.



Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

EPIDEMICS
Dutch 'ill-prepared' for cross-border nuclear accident: probe

Dutch to help tourism firms on storm-hit Caribbean isles

Researchers identify 'anxiety cells' inside the brains of mice

Stressed-out Dhaka to get 'Anger Management Park'

EPIDEMICS
Quantum control

Virtual reality goes magnetic

A frequency-doubling unit for transportable lasers

Pearly material for bendable heating elements

EPIDEMICS
Coastal water absorbing more carbon dioxide

Tiny Michigan town in water fight with Nestle

In the Galapagos, an idyllic hammerhead shark nursery

Paradise lost: 'Anote's Ark' shows Kiribati on the brink

EPIDEMICS
Arctic ponds potentially a major source of carbon emissions

Polar bears can't catch enough seals to stay fed: study

Arctic lakes are emitting young carbon

Heat loss from the Earth triggers ice sheet slide towards the sea

EPIDEMICS
More rice, please: 13 rice genomes reveal ways to keep up with ever-growing population

New Year canines stashed away in Muslim Malaysia

Australia toughens foreign investment rules amid China concerns

Vines from Napa, Bordeaux tough against heat, drought

EPIDEMICS
China launches electromagnetic satellite to study earthquake precursors

Gasps and awe as supermoon rises over erupting Philippine volcano

Guatemala volcano eruption subsides after 20 hours

Seine inches higher, keeping Paris on alert

EPIDEMICS
France freezes assets of DR Congo general over civilian 'massacres'

Mali mayor kidnapped by armed men: family

Benin's threatened Pendjari National Park gets $23.5m boost

Suicide bomber kills four Malian soldiers

EPIDEMICS
Lasers reveal ancient Mayan civilization hiding beneath Guatemalan canopy

Scandinavians shaped by several waves of immigration

Study details Peking Man's teeth

Modern human brain organization emerged only recently









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.